Shaping better health
REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Paediatric Joint Formulary

BNSSG Paediatric Recent Formulary Decisions

Checked: not set yet by Next Review: not set yet

4.4   Atomoxetine (Strattera®) (TLS Amber) SCP click here

  • ADHD in childhood


2.5.5 Captopril (tablets) (TLS Amber) SCP click here

  • Paediatric cardiology 


2.2.4 Chlorothiazide (TLS Red)

  • Neonates (unlicensed)


3.2 Flutiform® (fluticasone & Formoterol) (TLS Green)

  • in adolescents aged 12 and above


4.4 Methylphenidate - all formulations (TLS Amber) SCP click here

  • ADHD children & adolescents


Decision 29th May 2012 

Diamorphine nasal (Ayendi®) Paediatric analgesia (TLS Red)

  • Approved for the use in emergency departments and MIU


June 2013

14.5  Rotavirus live vaccine (Rotarix®) (TLS Green)

  • Active immunisation of infants from the age of 6 weeks for prevention of gastroenteritis due to rotavirus infection
  • Please see DoH/PHE FAQs for further information


October 2013

4.4 Lisdexamfetamine (TLS Red)

  • An alternative treatment for Attention deficit hyperactivity disorder when there has been an inadequate response to methylphenidate.


December 2013

13.8.1 Dundee Sunscreen (TLS Red)

  • When other reflectant sunscreens have failed


January 2014

1.Misc  Infloran (Bifidobacterium infantis, Lactobacillus acidophilus) (TLS Red)

  • For use in preterm infants less than 32 weeks gestation or < 1.5kg in weight until they reach at least 34 weeks corrected gestational age and have tolerated at least 2 weeks of enteral feeds.


September 2016

Clonidine Patches (TLS Red)

  • For patients with secondary dystonia and dyskinesia, according to UHBristol treatment pathway for Medical management of dystonia.


October 2016

Esomeprazole granules (TLS Red)

  • For patients with NG tubes or second line in children with swallowing difficulties.

3rd December 2019

Zanamivir (intravenous) (TLS Red)

  • for treatment of severe/ complicated influenza A or B virus infection where there is suspected resistance to anti-viral treatments other than zanamivir and who are unable to take oral or inhaled medication 

Budesonide orodispersible tablets (Jorveza®) (Amber 3 months)

Change from TLS Red to TLS Amber 3 months